Editor - Sumit Lal | Harvard Univeristy | 12430
ISSN: 1662-100X

Journal of Biomimetics Biomaterials and Tissue Engineering
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Sumit Lal

Sumit Lal
Sumit Lal
Junior Faculty (Instructor in Medicine)
Harvard Medical School
Harvard Univeristy


Dr. Sumit Lal is currently a junior faculty (Instructor in Medicine) at Harvard Medical School. Dr. Lal published more than 15 papers and 5 patents in the last 4 years. Dr. Lal has been awarded / offered many prestigious fellowships, prizes and funding awards including Harvard Medical School postdoctoral fellowship, Otago University postdoctoral fellowship and Endocrine research fellowship at Brigham & Women’s Hospital. Dr. Lal is a peer reviewer for 6 internationally circulated nanomaterials and nanotechnology journals including Nanomedicine: Nanotechnology, Biology and Medicine, Journal of Nanomedicine and Nanotechnology and International Journal of Nanomedicine.

Dr. Lal completed his PhD from The University of Auckland where he was awarded Bright Future Scholarship by Fonterra co-operative Ltd. Total grants and scholarships held by him as PI and co-PI amounts in excess of $400,000.

Research Interest

Dr. Lal’s research interest includes utilization of inorganic nanoparticles for applications in oncology, infectious diseases and allergies.

Projects that I currently mentor are:

1. Titanium dioxide nanoparticle based photocatalytic therapy for the treatment of skin, breast and colorectal cancer.

2. Gold nanostructure based photodynamic therapy for hyperthermic ablation, drug delivery and contrast enhancement in glioblastoma multiform and prostate cancer.

3. Super paramagnetic iron oxide nanoparticle (SPION) based hyperthermia therapy for therapeutic-diagnostics of prostate and breast cancer.


Relevant Topics